^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PY314

    i
    Other names: PY314, PY 314 , anti-PI-103
    Associations

    News

    Trials
    Company:
    Foundery Biosciences, ImageneBio
    Drug class:
    TREM2 inhibitor
    Associations

    News

    Trials
    over2years
    A Study of PY314 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=288, Active, not recruiting, Pionyr Immunotherapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • PY314
    over4years
    A Study of PY314 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=276, Recruiting, Pionyr Immunotherapeutics Inc. | Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • PY314
    5years
    A Study of PY314 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=216, Recruiting, Pionyr Immunotherapeutics Inc.
    Clinical • New P1 trial • Combination therapy • PD(L)-1 Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • PY314